THURSDAY, Sept. 17, 2020 (Healthday News) — The details of a plan to rapidly deliver a future coronavirus vaccine to Americans were unveiled by federal officials on Wednesday. Two of the key parts of the plan are to begin distributing a vaccine with 24 hours of any approval or emergency authorization and offering the vaccine for free, The New York Times reported. Officials from Operation Warp Speed — the multiagency effort to quickly vaccinate Americans against coronavirus — also said the timing of a vaccine was still unclear, the Times reported. That despite repeated statements from President Donald Trump that a shot could be ready before the election on Nov. 3. “We’re dealing in a world of great uncertainty. We don’t know the timing of when we’ll have a vaccine, we don’t know the quantities, we don’t know the efficacy of those vaccines,” Paul Mango, the deputy chief of staff for policy at the U.S. Department of Health and Human Services, told the Times. “This is a really quite extraordinary, logistically complex undertaking, and a lot of uncertainties right now. I think the message we want you to leave with is, we are prepared for all of those uncertainties.” Who will get the vaccine first? Initial distribution of a vaccine, possibly on an emergency basis, would to a limited group of high-priority people, such as…  read on >

Hearts donated by severely obese donors aren’t more risky for recipients than hearts from people who aren’t obese, a new study indicates. “These findings were somewhat surprising because the severely obese donors did tend to have more medical problems, such as diabetes and high blood pressure, than the non-obese donors,” said study author Dr. Leora Yarboro. She’s an associate professor of surgery at the University of Virginia, in Charlottesville. Her team analyzed the outcomes of 26,000 heart transplants in the United States from 2003 to 2017. About 3.5% of the donors were severely obese. There were no significant differences in short-term outcomes, one-year survival rates or long-term death rates between patients who received a heart from a severely obese donor and those who received a heart from a non-obese donor, the findings showed. The researchers also found that the percentage of heart transplants from donors with severe obesity rose from 2.2% in 2013 to 5.3% in 2017. Some of the obese donors did have other medical issues: 10% had diabetes versus 3% of non-obese donors, and 33% had high blood pressure versus 15% of donors who weren’t severely obese. The study was published Sept. 16 in the journal Circulation: Heart Failure. “This study shows that with careful selection, hearts from obese donors can be used without an increased risk to the recipient,” Yarboro said in…  read on >

WEDNESDAY, Sept. 16, 2020 (Healthday News) — A single infusion of an experimental drug dramatically lowers levels of coronavirus in the bodies of newly infected patients and cuts their chances of hospitalization, the drug’s maker reported Wednesday. Eli Lilly’s announcement did not include detailed data and hasn’t been peer-reviewed or published yet, The New York Times reported. The news comes from interim results of a trial sponsored by Eli Lilly and the U.S. National Institutes of Health. NIH officials would not comment on the announcement until they have seen more detailed data from the trial, the Times reported. How does the drug work its magic? It is a monoclonal antibody, a manmade copy of an antibody produced by a patient who recovered from COVID-19, the Times reported. Scientists around the world have high hopes that that monoclonal antibodies will prove to be powerful coronavirus treatments, but they come with a caveat: They are difficult to manufacture, and would take time to produce, the Times reported. In the trial, 452 newly diagnosed COVID patients received the monoclonal antibody or a placebo infusion. Some 1.7 percent of those who got the drug were hospitalized, compared with 6 percent of those who received a placebo — a 72 percent reduction in risk, Eli Lilly said. At the same time, blood levels of the coronavirus plummeted among those who…  read on >

HVAC repairman Brad Sissell shrugged off the acid-yellow air surrounding him and kept working, preparing a gas pipe for a new range going into a Salem, Ore., home. Less than a half-hour’s drive away, nearly 200,000 acres were burning in one of the major Oregon wildfires that has sent a full tenth of the state’s population fleeing for shelter. But it was a workday and so Sissell kept at his job, masked in the driveway with smoke wreathing his efforts. “We haven’t stopped,” Sissell, 35, said. “We’ve been working the whole time. I know they say the air’s not good for you. I think it’s going to suck for everybody.” The air quality index in Salem has been at the hazardous level since late last week, with people urged to stay indoors lest they risk their health. In fact, the West Coast cities of Portland, Seattle, San Francisco and Vancouver, B.C., have had the worst air quality of all major metropolitan areas in the world as wildfires burn unchecked, the Washington Post reported. Public health experts have warned people up and down the coast to remain indoors with the windows shut and their air conditioners running on recirculated air. The smoke from these wildfires contains fine particles and a toxic mix of chemicals that can irritate the lungs and inflame the airways, said Dr. Clayton…  read on >

TUESDAY, Sept. 15, 2020 (Healthday News) — In a sign that Americans are becoming more wary about the safety of a new coronavirus vaccine, a new poll shows a majority of adults don’t trust what President Donald Trump has said on vaccine development. More than half (52%) of adults said they don’t trust the president’s vaccine comments, the NBC News/Survey Monkey poll found, while just 26 percent say they do. Twenty percent said they were “not aware” whether they trust what the president has said about a vaccine, NBC News reported. Those polled were also more skeptical about whether they or their families would get a government-approved coronavirus vaccine if one became widely available, NBC News reported. The poll’s latest data show that just 39% said they would get it, 23% said they wouldn’t and 36 percent say they weren’t sure. Just a month ago, 44% of Americans said they would get a government-approved vaccine, 22% said they wouldn’t, and 32% said they weren’t sure. The highest level of confidence in a coronavirus vaccine came during the week of Aug. 17 to Aug. 23, when 45% polled said they would get a vaccine. Despite public hesitancy, President Trump has promised a “safe and effective vaccine this year,” and the U.S. Centers for Disease Control and Prevention has advised states to prepare for “large-scale” vaccine distribution…  read on >

MONDAY, Sept. 14, 2020 (Healthday News) — Oxford University has announced that final-stage testing of a coronavirus vaccine it is developing with drug maker AstraZeneca will restart following a pause last week after a serious side effect showed up in a volunteer. “The independent review process has concluded and following the recommendations of both the independent safety review committee and the U.K. regulator… the trials will recommence in the U.K.,” the university said in a statement released on Saturday. No further details were given on the results of the review. Media reports have said the person who had the suspected adverse reaction had been volunteering in a trial based in the United Kingdom. The volunteer was diagnosed with transverse myelitis, an inflammatory syndrome that affects the spinal cord and is often sparked by viral infections. The AstraZeneca vaccine is considered a frontrunner among the dozens of coronavirus vaccines in various stages of testing around the world, the Associated Press reported. The university said in large trials “it is expected that some participants will become unwell and every case must be carefully evaluated to ensure careful assessment of safety.” Globally, some 18,000 people have received its vaccine so far, the AP reported. Two other vaccines are in final testing in the United States, one made by Moderna Inc. and the other by Pfizer and Germany’s BioNTech.…  read on >